{"paper_id":"375bc0d5-5496-4186-9c9e-e04e11e41e00","body_text":"Lone Hummelshoj, \nWorld Endometriosis Research Foundation, London, UK.\nDaniëlle Peterse, \nVascular Biology Program, Boston Children’s Hospital, Department of Surgery, Harvard Medical School, Boston, MA, USA.\nKaylon L Bruner-Tran, \nWorld Endometriosis Research Foundation, London, UK; \nDepartment of Obstetrics and Gynecology, Vanderbilt University Medical Center, Nashville, TN, USA.\nStacey A Missmer, \nWorld Endometriosis Research Foundation, London, UK; \nDepartment of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, USA; \nDepartment of Epidemiology, Harvard TH Chan School of Public Health, Boston, MA, USA.\nErin Greaves, \nWorld Endometriosis Research Foundation, London, UK; \nDivision of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK.\n\nThis work was funded by the World Endometriosis Research Foundation.\n\nL.H. receives remuneration from WERF as the EPHect programme manager and has provided consultancy to Gesynta Pharma AS, which has no bearing on this work. D.P. reports no conflict of interest. K.L.B.-T. is a trustee of WERF. S.A.M. is a trustee of WERF, co-principal investigator of EPHect, a past president of the World Endometriosis Society (WES), and a member of the scientific advisory board of NextGen Jane; she has received presentation remuneration from Gideon Richter, and research funding from AbbVie, LLC, the Marriott Family Foundations, the USA National Institutes of Health (NIH), and the USA Peer Reviewed Medical Research Program (PRMRP), none of which is related to this work. E.G. is a member of the scientific advisory board of FimmCyte AG and a trustee of WERF.","source_license":"CC0","license_restricted":false}